OVs have been established as strong in situ anti-cancer vaccines (9, 14, 24, 29, 32) that activate antigen presenting cells (APCs), augment antigen processing and presentation, and prime CD8+ T cell responses (9). The gene discussed is CD8A; the disease is cancer.